Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care

Beatriz del Río-Muñoz, Cristina Azanza-Munarriz, Noelia Becerril-Ríos, Haydee Goicochea-Briceño, Rosalía Horno, Alejandro Lendínez-Mesa, César Sánchez-Franco, Mònica Sarmiento, Guillermo Bueno-Gil, Nicolás Medrano, Jorge Maurino

ABSTRACT

BACKGROUND: Nurses play an essential role in coordinating the care of patients with multiple sclerosis (MS) throughout their disease trajectory in a complex treatment landscape. The aim of this study was to assess nurses’ preferences toward different disease-modifying therapy attributes. METHODS: We conducted a multicenter, noninterventional, cross-sectional study in collaboration with the Sociedad Española de Enfermería Neurológica. Nurses actively involved in MS care were invited to participate in the study. Prevention of disability progression, preservation of cognitive function, side effect profile and safety monitoring, and method of administration were the treatment attributes tested. Conjoint analysis was used to assess preferences in 8 simulated treatment options and rank them from most to least preferred. RESULTS: A total of 98 nurses were included in the study. The mean (SD) age was 44.7 (9.8) years, and 91.8% were female with a mean (SD) time of experience in MS care of 7.5 (5.4) years. Participants prioritized preservation of cognition (38.6%), followed by preventing disability progression (35.2%) and side effect risk and safety monitoring (13.5%). Route and frequency of administration were the least preferred attributes (7.4% and 5.3%, respectively). Estimated utilities were consistent across the sample according to sociodemographic and professional practice characteristics. CONCLUSIONS: Nurses’ preferences toward treatments were mainly driven by efficacy attributes. This information may support the role of nurses in the multidisciplinary management of MS facilitating shared decision making.

Keywords: conjoint analysis, disease-modifying treatments, multiple sclerosis, nursing research, treatment preferences

Questions or comments about this article may be directed to Jorge Maurino, MD, at jorge.maurino@roche.com. Medical Department, Roche Farma, Madrid, Spain.

Beatriz del Río-Muñoz, is a Clinical and Research Nurse, Department of Neurology, Hospital Universitario de La Princesa, Madrid, Spain.

Cristina Azanza-Munarriz, is a Clinical and Research Nurse, Department of Neurology, Complejo Hospitalario de Navarra, Pamplona, Spain.

Noelia Becerril-Ríos, is a Clinical and Research Nurse, Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.

Haydee Goicochea-Briceño, is a Clinical and Research Nurse, Department of Neurology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Rosalía Horno, is a Clinical and Research Nurse, Centre d’Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain.

Alejandro Lendínez-Mesa, PhD, is a Clinical and Research Nurse, Department of Nursing, School of Medicine, Universidad Alfonso X el Sabio, Madrid, Spain.

César Sánchez-Franco, is a Clinical and Research Nurse, Department of Neurology, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.

Mònica Sarmiento, Health Economics and Outcomes Research, IQVIA Information SA, Barcelona, Spain.

Guillermo Bueno-Gil, MSc, Medical Department, Roche Farma, Madrid, Spain.

Nicolás Medrano, MD, Medical Department, Roche Farma, Madrid, Spain.

This study was funded by Roche Medical Department, Spain (SL42129). Guillermo Bueno-Gil, Nicolás Medrano and Jorge Maurino are employees of Roche Farma Spain. The rest of authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.jnnonline.com).

Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

https://doi.org/10.1097/JNN.0000000000000661
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that mainly affects young people and is associated with physical and cognitive impairment and loss of functional autonomy. The spectrum of disease-modifying therapies (DMTs) has grown substantially in the last 10 years, allowing for individualized disease management and more ambitious therapeutic goals. In this context, nurses have an essential role in identifying the perceptions and needs of patients and caregivers at all stages of the disease according to the Neuman system model. They usually participate in patient education and aspects related to disease care as well as on how treatments are administered, the importance of adherence, and potential side effects. In addition, their close and frequent interaction with patients gives them the opportunity to detect more subtle symptoms that are often overlooked in follow-up office visits by neurologists.

Although nurses cannot prescribe DMTs, understanding their treatment preferences and priorities may help to improve their role in a complicated treatment landscape with different side effect profiles and safety monitoring needs. The aim of this study was to assess nurses’ preferences toward relapsing-remitting MS treatments according to different attributes of efficacy, safety, and mode of administration.

Methods
This is a multicenter, noninterventional, cross-sectional, Web-based study conducted in collaboration with the Sociedad Española de Enfermería Neurológica. Nurses with experience managing MS patients received an email from the Sociedad Española de Enfermería Neurológica with the invitation to participate in the study. This email included a link to access the study website. This study was approved by the Hospital Universitario Clínico San Carlos (Madrid, Spain) research board. A written informed consent was obtained from all participants.

Conjoint analysis is a well-established and validated approach to assess the value that people allocate to the different characteristics of medical interventions. Preference elicitation using conjoint analysis has been studied in MS involving different healthcare professionals and patients. Treatment attributes and levels were originally designed by our research team of 7 nurses specialized in MS after reviewing clinical trials and patient preference research literature. Prevention of disability progression, preservation of cognitive function, route and frequency of administration, and side effect risk and safety monitoring were the 5 attributes selected (Supplemental Digital Content 1, available at http://links.lww.com/JNN/A420). An orthogonal design was applied to design 8 simulated treatment options containing unique combinations of attributes and levels (Supplemental Digital Content 2, available at http://links.lww.com/JNN/A421). Participants ranked treatment options from 1 (most preferred) to 8 (least preferred).

In addition, participants had to answer questions related to sociodemographic and professional practice characteristics, and completed questionnaires to measure nurses’ attitude toward the adoption of medical innovations, coping strategies, workplace burnout, and healthcare-related regret. The Evidence-Based Practice Attitude Scale is a high–psychometric-quality instrument used to measure attitudes toward adopting new treatments, interventions, and practices among healthcare providers. It consists of 15 items rated on a 5-point Likert-type scale, ranging from 0 (not at all) to 4 (to a very great extent). Higher scores indicate a more positive attitude toward innovations. The Brief-COPE is a validated 28-item questionnaire designed to measure effective and ineffective ways to cope with a stressful life event. Higher scores indicate increased utilization of the specific coping strategy. Occupational burnout was assessed using the 9 items of the emotional exhaustion dimension of the Maslach Burnout Inventory-Human Services Survey. A score of 27 or greater indicates high emotional exhaustion. The 10-item Regret Intensity Scale is a validated tool used to assess regret caused by a past event, covering affective, physical, and cognitive aspects. Higher scores indicate higher regret intensity.

Statistical Analysis
The ordinary least squares method was used to estimate parameters. Results were summarized in terms of utilities (profits), relative (overall), and individual importance assigned to each attribute. The Kendall correlation coefficient between real ranges and those predicted by the model was used to assess the goodness of fit of the model. The relative importance of each factor was obtained by dividing the importance of a factor by the sum of all individual importance scores. A model fits the data well if the differences between the observed values and the predicted values are small and unbiased. The closer the coefficient is to 1, the better the model.

An exploratory k-means cluster analysis based on individual profits to different attributes was used to identify possible profiles of nurses with similar preferences. Differences in sociodemographic and professional practice characteristics as well as behavioral factors were assessed between clusters.

Results
Overall, 331 nurses were invited to participate, 130 initiated the study (39.3%), and 98 completed the study (29.6%). The mean (SD) age was 44.7 (9.8) years,
and 91.8% were female. Almost 50% worked at a hospital-based outpatient clinic with a mean (SD) time of experience managing MS of 7.5 (5.4) years. Main demographic and professional practice characteristics are shown in Table 1.

Treatment option E was the most chosen by the participants. Nurses prioritized the preservation of cognition (38.6%), followed by preventing disability progression (35.2%) and side effect risk and safety monitoring (13.5%). Similar values were obtained with average importance (Table 2). Preserving cognition and preventing disability progression also were the most preferred attributes according to the utilities scores (Table 2). Overall, mode of administration was the least preferred attribute, although self-administration and administration over longer periods were the most valued in these 2 dimensions. Pearson $R$ and Kendall $\tau$ coefficients showed a high correlation: 1000 ($P < .001$)

| TABLE 1. Demographic and Professional Practice Characteristics of the Sample |
|-----------------------------|-----------------|------------------|
| Sex                        | Female, n (%)   | 90 (91.8)        |
| Age, y                     | Mean (SD)       | 44.7 (9.8)       |
|                           | >40, n (%)      | 65 (66.3)        |
| Work experience, y         | As a hospital nurse, mean (SD) | 21.1 (9.9) |
|                           | Managing patients with MS, mean (SD) | 7.5 (5.4) |
| Work setting               | Outpatient clinic, n (%) | 48 (49.0) |
|                           | IV center, n (%) | 33 (33.7)        |
| MS patients managed per week | Mean (SD)       | 23.9 (22.6)      |
| Training and professional activities | Participation in MS clinical trials, n (%) | 61 (62.2) |
|                           | Authorship of scientific manuscripts/abstracts in peer-reviewed journals/congresses, n (%) | 73 (74.5) |
|                           | Attendance to MS training activities in the last 2 y, n (%) | 89 (90.8) |

| TABLE 2. Utility Scores and Importance Assigned to Each Attribute and Level |
|--------------------------------------|-----------------|-----------------|
| Cognition                            | Utility Estimation (SE) | Importance (Relative) | Importance (Averaged) |
| No cognitive impairment              | 1.245 (0.040)   | 38.6%            | 32.7%            |
| Cognitive impairment                 | −1.245 (0.040)  |                 |                 |
| Disease progression                  |                 |                 |                 |
| No progression in 2 y                | 1.133 (0.040)   | 35.2%            | 31.7%            |
| Progression in 2 y                   | −1.133 (0.040)  |                 |                 |
| Safety and nurse monitoring          |                 |                 |                 |
| Infrequent but severe AE plus monitoring 1–2 times a month | −0.434 (0.040) | 13.5%            | 14.2%            |
| Frequent but mild-moderate AE plus monitoring every 3–6 mo | 0.434 (0.040) |                 |                 |
| Route of administration              |                 |                 |                 |
| Self-administered                    | 0.240 (0.040)   | 7.4%             | 10.0%            |
| Hospital administration              | −0.240 (0.040)  |                 |                 |
| Frequency of administration           |                 |                 |                 |
| At least twice a month               | −0.143 (0.053)  | 5.3%             | 11.4%            |
| Monthly                               | −0.056 (0.062)  |                 |                 |
| Every 6 mo                            | 0.199 (0.062)   |                 |                 |

Abbreviations: IV, intravenous; MS, multiple sclerosis.

Positive values indicate a greater preference for an attribute.
and 1000 (P < .001), respectively. Estimated utilities were consistent across the sample according to socio-demographic and professional practice characteristics.

Two participant clusters were identified based on the prioritization assigned to each attribute. Cluster 1 included 78 (79.6%) nurses prioritizing treatments that preserve cognition and prevent disability progression. Cluster 2 included 20 nurses prioritizing route and frequency of administration of treatments. Cluster 1 participants showed a higher intensity of regret compared with cluster 2 participants (mean [SD] 10-item Regret Intensity Scale score, 2.2 [0.9] and 1.6 [0.7], respectively; P = .01) (Supplemental Digital Content 3, available at http://links.lww.com/JNN/A422). Cluster 2 nurses managed a higher mean rate of MS patients per week compared with patients with other neurological diseases than cluster 1 participants (58.5% and 42.6%, respectively; P = .04) and also showed a higher level of denial (mean [SD] Brief COPE denial score, 1.9 [2.1] and 0.9 [1.2], respectively; P = .008) (Supplemental Digital Content 3, available at http://links.lww.com/JNN/A422). No other differences in demographic, professional practice, and behavioral characteristics were found between groups.

Discussion

Current management of MS poses many challenges for healthcare professionals.5,6,24 By focusing on coordinating the care of MS patients throughout the disease trajectory, nurses can capture different types of information and support neurologists in the treatment decision-making process.5,6,27,28

In this study, preserving cognition and delaying disability progression were the most chosen DMT attributes among nurses with experience managing MS in Spain. The importance of understanding perspectives toward MS DMTs has been explored mainly in patients.19 Research on treatment preferences among healthcare professionals caring for MS has been less studied. Tencer et al29 found that reducing the rate of brain volume loss was the most important treatment attribute among 101 neurologists from the United Kingdom, followed by risk of infections and progression of disability at 2 years. Delaying disease progression was the most prioritized treatment attribute in a study involving 65 hospital pharmacists in Spain, followed by preserving quality of life and cognition.18

There are very few studies of therapeutic goals aimed at understanding the perspective of nurses caring for MS patients, and they are mainly oriented toward their perception of tolerability of different drugs and advantages of autoinjectors.30-32 Peloquin et al8 investigated knowledge and attitudes regarding MS care among 135 nurses from France, Germany, Italy, Spain, Canada, United States, and the United Kingdom. Participants reported knowledge gaps on new DMTs available (51%), treatment sequencing (46%), and detection of treatment failure (52%). Most participants also reported difficulties interpreting certain neurological assessments and outcomes (eg, Timed 25-Foot Walk Test, no evidence of disease activity, no evidence of progression or active disease).7 In a study with nurses and neurologists from the Netherlands, risk of life-threatening or severely disabling adverse events was the most important attribute in treatment decision, followed by effects on disability, frequency of relapses, and quality of life.17 Both groups did not differ significantly in their perspective about which attributes were most important for making decisions, with statistical differences only being found in 2 low prioritized attributes (costs were ranked higher by neurologists and drug interactions were ranked higher by nurses).17

These results show that all healthcare professionals involved in MS care in Spain are aligned on the increasing importance of impacting disease progression with the goal of preventing disability. In our study, we found that a subset of nurses (20.4%) prioritized route and frequency of administration as the most important attributes of treatments. They had a higher rate of MS patients managed per week and a higher coping component of denial compared with those participants who prioritized efficacy attributes. We hypothesize that a higher workload may have influenced this preference for treatment options that are easier to administer and/or have lower safety monitoring requirements.

Our study has limitations that deserve mention. First, the limited availability of studies on treatment preferences in MS nurses determined that the selection of treatment attributes and levels in this study was based primarily on previous studies conducted in patients and neurologists. Second, the selection of few treatment attributes to avoid complex study design and difficulty in selecting preferences could have caused omitted variable bias owing to exclusion of additional key attributes already identified in previous studies, such as the relapse prevention rate.33 Third, nurses are not the final decision-makers in prescribing MS treatments, and we have not captured their knowledge of the different efficacy and safety characteristics of currently available agents. Finally, nurses may have different responsibilities and activities in MS care depending on the country where they work. Therefore, these results may not necessarily be representative in other countries.

Conclusion

This study showed that preserving cognitive function and reducing disability progression are the most valued DMT attributes among nurses caring for patients with MS. The understanding of nurses’ preferences
may support their role in the multidisciplinary management of MS facilitating shared decision making by patients and neurologists.

Acknowledgments

The authors are most grateful to the Sociedad Española de Enfermería Neurológica and all nurses who participated in the study.

References

1. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779. doi:10.1001/jama.2020.26858

2. Maurino J, Martínez-Ginés ML, García-Dominguez JM, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis. Mult Scler Relat Disord. 2020;41:102046. doi:10.1016/j.msard.2020.102046

3. Linker RA, Chan A. Navigating choice in multiple sclerosis management. Neurol Res Pract. 2019;1:5. doi:10.1186/s42466-019-0005-5

4. Tsantes E, Curti E, Collura F, Bazzurri V, Fiore A, Granella F. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. J Neurol Sci. 2020;414:116827. doi:10.1016/j.jns.2020.116827

5. Meehan M, Doody O. The role of the clinical nurse specialist in multiple sclerosis, the patients' and families' and carers' perspective: an integrative review. Mult Scler Relat Disord. 2020;40:101918. doi:10.1016/j.msard.2019.101918

6. Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratín P, Comi G. The multiple sclerosis care unit. Mult Scler. 2019;25(5):627–636. doi:10.1177/1352458518807082

7. Weilenmann M, Händler-Schuster D, Petry H, Zanolari D, Schmid-Mohler G, Beckmann S. Patient satisfaction with the quality of counselling provided by advanced practice nurses specialized in multiple sclerosis: a quantitative analysis. J Neurol Sci. 2021;53(2):99–103. doi:10.1097/JNS.000000000000578

8. Peloquin S, Schmierer K, Leist TP, Oh J, Murray S, Lazure P. Challenges in multiple sclerosis care: results from an international mixed-methods study. Mult Scler Relat Disord. 2021;50:102854. doi:10.1016/j.msard.2021.102854

9. Schmid F, Rogan S, Glässel A. A Swiss health care professionals’ perspective on the meaning of interprofessional collaboration in health care of people with MS—a focus group study. Int J Environ Res Public Health. 2021;18(12):6537. doi:10.3390/ijerph18126537

10. Cameron E, Rog D, McDonnell G, Overell J, Pearson O, French DP. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: a qualitative interview study. Mult Scler Relat Disord. 2019;27:378–382. doi:10.1016/j.msard.2018.11.023

11. Price E, Lucas R, Lane J. Experiences of healthcare for people living with multiple sclerosis and their healthcare professionals. Health Expect. 2021;24(6):2047–2056. doi:10.1111/hex.13348

12. Parker LS, Topegu D, De Boos D, das Nair R. The notion of "invisibility" in people’s experiences of the symptoms of multiple sclerosis: a systematic meta-synthesis. Disabil Rehabil. 2021;43(23):3276–3290. doi:10.1080/09638288.2020.1741698

13. Marck CH, Hunter A, Butler E, et al. Assessment and treatment of depression in people with multiple sclerosis: a qualitative analysis of specialist clinicians’ experiences. Mult Scler Relat Disord. 2022;57:103362. doi:10.1016/j.msard.2021.103362

14. Luechetta RC, Leonart LP, Becker J, Pontarolo R, Fernandez-Llimós F, Wiens A. Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. Mult Scler Relat Disord. 2019;35:7–15. doi:10.1016/j.msard.2019.06.036

15. Bridges JF, Hauber AB, Marshall D, et al. Conjunct analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013

16. Farley K, Thompson C, Hanbury A, Chambers D. Exploring the feasibility of conjoint analysis as a tool for prioritizing innovations for implementation. Implement Sci. 2013;8:56. doi:10.1186/1748-5908-8-56

17. Kremer IEH, Evers SMAA, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling. Health Expect. 2018;21(1):171–180. doi:10.1111/hex.12599

18. Martínez-López I, Maurino J, Sammartin-Fenollera P, et al. Assessing pharmacists’ preferences towards efficacy attributes of disease-modifying therapies in relapsing-remitting multiple sclerosis. Pharmacy. 2020;8(2):61. doi:10.3390/pharmacy8020061

19. Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929. doi:10.1016/j.msard.2020.101929

20. Uitdehaag BMJ. Disability outcome measures in phase III clinical trials in multiple sclerosis. CNS Drugs. 2018;32(6):543–558. doi:10.1007/s40263-018-0530-8

21. Santesson AHE, Bäckström M, Holmberg R, Perrin S, Jarbin H. Confirmatory factor analysis of the Evidence-Based Practice Attitude Scale (EBPAS) in a large and representative Swedish sample: is the use of the total scale and subscale scores justified? BMC Med Res Methodol. 2020;20(1):254. doi:10.1186/s12874-020-01126-4

22. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56(2):267–283. doi:10.1037/0022-3514.56.2.267

23. Maslach C, Jackson SE, Leiter MP. Maslach Burnout Inventory Manual. 4th ed. Menlo Park, CA: Mind Garden, Inc; 2018.

24. Saposnik G, Bueno-Gil G, Sempere ÁP, et al. Regret and therapeutic decisions in multiple sclerosis care: literature review and research protocol. Front Neurol. 2021;12:675520. doi:10.3389/fneur.2021.675520

25. Courvoisier DS, Cullati S, Haller CS, et al. Validation of a 10-item care-related Regret Intensity Scale (RIS-10) for health care professionals. J Med Care. 2020;63(5):338–352. doi:10.1097/mlr.0000000000000078

26. Oreja-Guevara C, Potra S, Bauer B, et al. Joint healthcare and research protocol. Adv Ther. 2019;36(11):3238–3252. doi:10.1007/s12265-019-01071-9

27. Roman C, Menning K. Treatment and disease management of multiple sclerosis patients: a review for nurse practitioners. J Am Assoc Nurse Pract. 2017;29(10):629–638. doi:10.1002/1719-8480.12325-019-01071-9

28. Robles-Sanchez MA, Cruz-Díaz V, Amil-Bujan P, Sastre-Garriga J, Ramíó-Torrentà L, Bertran-Noguer C. An expert patient program as a tool to empower people with multiple sclerosis. J Neurol Sci. 2020;52(4):166–171. doi:10.1097/JNN.0000000000000514
29. Tencer T, Will O, Kumar J, Cambron-Mellott MJ, Maekie DS, Beusterien K. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment. *Curr Med Res Opin*. 2021; 37(9):1589–1598. doi:10.1080/03007995.2021.1940911

30. Verdun di Cantogno E, Tomlinson M, Manuel L, Thakur K. Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA. *Pragmat Obs Res*. 2014; 5: 53–64. doi:10.2147/POR.S72012

31. Campbell TL, Lefaux BJ, Mayer LL, et al. Nursing management of gastrointestinal adverse events associated with delayed-release dimethyl fumarate: a global Delphi approach. *J Neurosci Nurs*. 2020; 52(2):72–77. doi:10.1097/JNN.0000000000000495

32. White S, Harris C, Allan M, et al. Global peginterferon beta-1a tolerability management best practices: a nurse-focused Delphi approach. *Neurol Ther*. 2021; 10(1):251–263. doi:10.1007/s40120-021-00238-3

33. Coast J, Flynn TN, Salisbury C, Louviere J, Peters TJ. Maximising responses to discrete choice experiments: a randomised trial. *Appl Health Econ Health Policy*. 2006; 5(4): 249–260. doi:10.2165/00148365-200605040-00006